Singulair News
Most Popular Singulair Story
Merck's diabetes drugs offset Remicade sales decline
Merck ($MRK) managed to beat analyst estimates for fourth-quarter profits and supply slight sales growth of 2%. That's saying something during a quarter when some drugmakers saw profits drop by half Read more...
Latest Headlines
- February 2, 2012
- November 22, 2011
- October 24, 2011
- December 18, 2009
- August 20, 2009
- June 15, 2009
- May 29, 2009
- February 19, 2009
- November 6, 2008
- September 11, 2008
- September 3, 2008
- August 7, 2008
- June 10, 2008
- April 28, 2008
- April 23, 2008
- April 16, 2008
- March 28, 2008
- December 4, 2007
- October 22, 2007
- August 28, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
